A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma

WHO Hepatitis C. Fact Sheet no. 164, 2014, http://www.who.int/mediacentre/factsheets/fs164/en/

Butt, 2012, Boceprevir and telaprevir in the management of hepatitis C virus-infected patients, Clin. Infect. Dis., 54, 96, 10.1093/cid/cir774

Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N. Engl. J. Med., 364, 2405, 10.1056/NEJMoa1012912

EASL, EASL Recommendations on treatment of hepatitis C 2015, http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf

Kirby, 2015, Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir, Clin. Pharmacokinet., 54, 677, 10.1007/s40262-015-0261-7

Boglione, 2015, Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, Clin. Microbiol. Infect., 21, e201, 10.1016/j.cmi.2014.07.009

De Nicolò, 2014, Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner, Antivir. Res., 109, 7, 10.1016/j.antiviral.2014.06.005

Jiang, 2015, Multiplexed LC–MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma, J. Pharm. Biomed. Anal., 107, 409, 10.1016/j.jpba.2015.01.027

Kandoussi, 2015, A highly sensitive and selective LC–MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies, J. Pharm. Biomed. Anal., 119, 145, 10.1016/j.jpba.2015.11.028

Pan, 2015, Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 1008, 255, 10.1016/j.jchromb.2015.11.056

Rezk, 2015, Development of a sensitive UPLC-ESI–MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study, J. Pharm. Biomed. Anal., 114, 97, 10.1016/j.jpba.2015.05.006

Shi, 2015, Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 1002, 353, 10.1016/j.jchromb.2015.08.038

FDA, Guidance for Industry: Bioanalytical Method Validation (2013).

Taylor, 2005, Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray–tandem mass spectrometry, Clin. Biochem., 38, 328, 10.1016/j.clinbiochem.2004.11.007

de Kanter, 2014, Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations, Clin. Pharmacokinet., 53, 409, 10.1007/s40262-014-0142-5

De Nicolò, 2015, UPLC–MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients, J. Pharm. Biomed. Anal., 114, 127, 10.1016/j.jpba.2015.05.016